Abstract:Purpose Angiotropism is the process by which cancer cells attach to and migrate along blood vessels to acquire vasculature, disseminate, and metastasize. However, the molecular basis for such vessel–tumor interactions has not been fully elucidated, partly due to limited experimental models. In this study, we aimed to observe and explore the molecular mechanism underlying angiotropism in melanoma. Methods To monitor the interactions of human melanoma cells with the vasculature in vivo, a murine coxenograft model was employed by co-injecting highly and poorly invasive melanoma cells subcutaneously. To identify key pathways and genes involved in the angiotropic phenotype of melanoma, analysis of differentially expressed genes (DEGs) and gene set enrichment analysis (GSEA) were performed. The role of tissue factor pathway inhibitor 2 (TFPI2) in angiotropism was evaluated by immunostaining, adhesion assay, shRNA, and in vivo tumorigenicity. Angiotropism and TFPI2 expression were examined in surgical specimens of melanoma by immunohistochemical staining. Data from The Cancer Genome Atlas (TCGA) were analyzed to explore the expression and prognostic implications of TFPI2 in uveal and cutaneous melanoma. Results Highly invasive melanoma cells spread along the branches of intratumor blood vessels to the leading edge of invasion in the coxenograft model, resembling angiotropic migration. Mechanisms underlying angiotropism were primarily associated with molecular function regulators, regulation of cell population proliferation, developmental processes, cell differentiation, responses to cytokines and cell motility/locomotion. TFPI2 downregulation weakened the perivascular migration of highly invasive melanoma cells. High levels of TFPI2 were correlated with worse and better survival in uveal and cutaneous melanoma, respectively. Conclusion These results provide a straightforward in vivo model for the observation of angiotropism and suggest that TFPI2 could inhibit the angiotropic phenotype of melanoma.

Supplementary Figure 2 from Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition

Supplementary Figure 1 from Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition

Supplementary Figure 3 from Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition

Supplementary Figure 4 from Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition

Supplementary Figure 5 from Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition

Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Supplementary Figure 2 from RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma

Supplementary Figure S3 from Tracking and Functional Characterization of Epithelial–Mesenchymal Transition and Mesenchymal Tumor Cells During Prostate Cancer Metastasis

Supplementary Figure S1 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure.2 from the Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation

Supplemental Figure 2 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma

Supplementary Figures and Tables from Epidermal Growth Factor Receptor and PTEN Modulate Tissue Factor Expression in Glioblastoma Through JunD/Activator Protein-1 Transcriptional Activity

Supplementary Figure 2 from <i>Neuropilin-1</i> Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment

Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Figure S2 from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Figure 6 from A Regulatory Loop Involving miR-22, Sp1, and c-Myc Modulates CD147 Expression in Breast Cancer Invasion and Metastasis

TFPI2 Promotes Perivascular Migration in an Angiotropism Model of Melanoma

Supplementary Figure Legend from VEGFR-1 Expressed by Malignant Melanoma-Initiating Cells Is Required for Tumor Growth

Supplementary Figures 1-7 from Novel Oncogene–Induced Metastatic Prostate Cancer Cell Lines Define Human Prostate Cancer Progression Signatures